Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Recurso digital |
| Jazyk: | |
| Vydáno: |
Zenodo
2025
|
| On-line přístup: | https://doi.org/10.5281/zenodo.16640207 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1866901380493475840 |
|---|---|
| author | Mamoor, Shahan |
| author_facet | Mamoor, Shahan |
| contents | <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2). Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B disease. Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer. We describe one member of a group of phosphatases up-regulated and differentially expressed in human luminal B breast cancer, PGP, as a catalytically available phosphatase and candidate therapeutic target for the adjunctive medical treatment of luminal B breast cancer. </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_16640207 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Phosphatase targeting in Luminal B breast cancer: PGP. Mamoor, Shahan <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2). Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B disease. Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer. We describe one member of a group of phosphatases up-regulated and differentially expressed in human luminal B breast cancer, PGP, as a catalytically available phosphatase and candidate therapeutic target for the adjunctive medical treatment of luminal B breast cancer. </p> |
| title | Phosphatase targeting in Luminal B breast cancer: PGP. |
| url | https://doi.org/10.5281/zenodo.16640207 |